death drove the primary finding, as the rates of non-fatal MI and nonfatal stroke were not significantly different for empagliflozin and placebo. 6 In addition, the risk of heart failure hospitalisation and all-cause mortality was significantly reduced with empagliflozin vs placebo, 6 and empagliflozin treatment was associated with slower progression of kidney disease compared with placebo. 7 In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial in patients with T2DM and high cardiovascular risk, treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide was associated with a significant reduction in the risk of death from cardiovascular causes and a non-significant reduction in the risk of non-fatal MI, non-fatal stroke and hospitalisation for heart failure compared with placebo. 8 Findings from these and other cardiovascular outcome studies may, in time, lead to greater use of newer agents (such as SGLT2 inhibitors and GLP-1 receptor agonists) in patients at high cardiovascular risk. Recent European Cardiovascular Society guidelines on CVD prevention state that use of an SGLT2 inhibitor should be considered early in the course of diabetes management for patients with existing CVD based on observed reductions in CVD, total mortality and heart failure hospitalisations. 9 Use of SGLT2 inhibitors is also supported by the growing body of evidence on therapies that can provide multifactorial benefits, such as weight loss and reduced blood pressure (BP), in addition to lowering blood glucose. 4 ,10 SGLT2 inhibitors have been shown to provide clinically important improvements in glycaemic control and to induce mild osmotic diuresis, natriuresis and negative energy balance, which contribute to reductions in BP and body weight across a broad range of patients with T2DM. 11 Recent publications suggest that the cardioprotective effects seen with empagliflozin are likely to be relevant for the SGLT2 inhibitor class as a whole. [12] [13] [14] [15] [16] Although many of the improvements in cardiovascular risk factors have been reported for all SGLT2 inhibitors, this review article focuses on describing the effects of canagliflozin on cardiovascular risk factors based on results from its clinical development programme. Results
of the CANagliflozin cardioVascular Assessment Study (CANVAS)
Program 17, 18 will provide evidence on whether the observed effects on cardiovascular risk factors translate into cardiovascular benefits in patients with T2DM.
| EFFECTS OF CANAGLIFLOZIN TREATMENT ON CARDIOVASCULAR RISK FACTORS
Canagliflozin acts by inhibiting SGLT2, which is the primary mediator of renal glucose reabsorption. Such inhibition lowers the renal threshold for glucose excretion (RT G ), which increases urinary glucose excretion (UGE) and reduces plasma glucose levels in an insulinindependent manner. 19 Canagliflozin is indicated as an adjunct to diet and exercise for the treatment of adults with T2DM. 11 A summary of the impact of canagliflozin on cardiovascular risk factors is provided in Table 1 , along with an overview of the mechanisms that may contribute to these effects.
| Glycaemic effects
Chronic hyperglycaemia has been suggested to be a contributor to the increased risk of CVD in people with T2DM, 5 and glucose control is often considered to be a cornerstone of comprehensive cardiovascular risk reduction strategies. 20 However, based on findings from studies assessing cardiovascular risk in T2DM, such as ACCORD, ADVANCE and VADT, there is not universal agreement that lowering plasma glucose levels is a driver for improvements in cardiovascular outcomes.
These studies evaluated intensive glucose-lowering strategies with established therapies and reported negative or neutral effects on cardiovascular outcomes. [21] [22] [23] Thus, the American Diabetes Association and the European Association for the Study of Diabetes recommend treatment strategies that provide glycaemic control within a multifactorial cardiovascular risk reduction framework. 20 In a clinical trials programme that enrolled ~10 000 patients with T2DM, including older patients, patients with moderate renal impairment, and patients with elevated cardiovascular risk, treatment with canagliflozin 100 and 300 mg was associated with clinically significant, dose-dependent reductions in HbA1c, both as monotherapy and as part of combination therapy with metformin ± a sulphonylurea for up to 104 weeks. 11 In active-controlled Phase 3 studies, canagliflozin 300 mg provided greater reductions in HbA1c compared with both glimepiride and sitagliptin.
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In addition to reducing HbA1c levels, the increase in UGE that occurs with canagliflozin treatment is associated with reductions in postprandial glucose and insulin excursions. 11, 19, [24] [25] [26] [27] Further reductions in postprandial glucose also occur through a non-renal mechanism.
While data indicate that canagliflozin does not have systemic effects
Review criteria
Structured searches were performed to identify published literature related to the effects of the SGLT2 inhibitor canagliflozin on cardiovascular risk factors in patients with T2DM. Articles and congress abstracts identified in these searches were evaluated for clinical data on the effects of canagliflozin on cardiometabolic outcomes and for information about potential mechanisms associated with these effects. This intestinal SGLT1 inhibition may slow glucose absorption from the morning meal and delay the appearance of glucose in plasma. 24 It has been hypothesised that such reductions in postprandial hyperglycaemia and insulin variability may have a greater impact on reducing cardiovascular risk than simply reducing average blood glucose levels (ie, HbA1c) because processes that trigger oxidative stress and endothelial dysfunction are often upregulated when glucose levels peak or fluctuate widely between high and low levels. 30 The glycaemic efficacy of canagliflozin is largely independent of beta-cell function and insulin sensitivity. 31 Thus, it is not surprising that canagliflozin has been shown to significantly improve glycaemic control in patients with T2DM across a range of ages, weight/ Results are mixed on CV effects of increased haemoglobin/haematocrit Increases in the EMPA-REG OUTCOME study were associated with improvements in HF and mortality risk, but may increase risk of thrombotic events Ketones ↑ Shift in substrate delivery to the heart and changes in cardiac insulin sensitivity Improvements in myocardial and renal fuel metabolism may reduce CV risk, but there is also speculation about increased risk of thrombotic events CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density lipoprotein cholesterol; SGLT2i, sodium glucose co-transporter 2 inhibitors; T2DM, type 2 diabetes mellitus.
Message for the clinic
a Arrows indicate the direction of statistically significant changes associated with canagliflozin treatment.
body mass index categories, baseline HbA1c levels and disease durations. 32, 33 The risk of hypoglycaemia is generally low with canagliflozin when it is used alone or in combination with other AHAs that have a low intrinsic risk of causing hypoglycaemia. 11 A post hoc analysis of data from a Phase 3 study in patients with T2DM inadequately controlled on metformin showed that a higher proportion of patients achieved their glycaemic goals (ie, HbA1c <7% or <6.5%) without hypoglycaemia after 52 weeks of treatment with canagliflozin vs the sulphonylurea glimepiride. 34 Notably, hypoglycaemia may be associated with an increased risk of cardiovascular events.
The Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial compared an insulin strategy with standard care using oral AHAs in patients with early T2DM who were at a high risk for cardiovascular outcomes. It was observed that patients who experienced severe hypoglycaemia (ie, requiring assistance or glucose ≤2.0 mmol/L [≤36 mg/dL]) had significantly increased risks for the composite of cardiovascular death, non-fatal MI or stroke, as well as all-cause mortality, cardiovascular death and arrhythmic death. 35 It remains to be seen if the low risk of hypoglycaemia that is associated with canagliflozin treatment will also be associated with improved cardiovascular outcomes.
| Effects on insulin secretion/resistance
In patients with T2DM, insulin resistance has been shown to develop in target tissues, including liver, adipose, muscle and myocardium. Insulin resistance is a major driver of adverse cardiovascular outcomes that acts synergistically with hyperglycaemia to promote atherosclerosis. 36 Specifically, reduced insulin signalling in endothelial tissue is associated with increased vascular dysfunction, inflammation, oxidative stress and the development of atherosclerotic lesions. 36 Analysis of data from three Phase 3 studies of canagliflozin as monotherapy and as add-on to metformin plus sulphonylurea showed that 6-12 months of canagliflozin treatment improves both fasting and postprandial measures of beta-cell function and insulin secretion. 37 Insulin secretion rate was significantly increased with canagliflozin compared with baseline at all plasma glucose concentrations (7-16 mmol/L); these increases were of similar magnitude with canagliflozin vs sitagliptin. 37 Insulin sensitivity, measured using the oral glucose insulin sensitivity index corrected for UGE, also improved by approximately 15% with canagliflozin treatment. 37 It has been hypothesised that such improvements in insulin sensitivity are a result of weight loss and the reversal of glucotoxicity. Improvement in hyperinsulinaemia may reduce the risk of atherosclerosis beyond that of glucose lowering alone. 5, 38 In a rodent model, Watanabe and colleagues showed that the combination of canagliflozin with pioglitazone reduced hyperinsulinaemia and improved whole-body insulin sensitivity compared with pioglitazone monotherapy. 39 Further studies are needed to confirm whether indirect improvement in insulin sensitivity of the magnitude observed in studies of canagliflozin has a significant effect on atherosclerosis risk in people with T2DM. 
| Effects on body weight and adiposity
Modest weight loss of between 5% and 10% can contribute to improvements in glycaemic control and may reduce CVD risk factors in overweight and obese patients with T2DM. 40 While overall results from the Look AHEAD study in overweight or obese patients with T2DM did not find an association between intensive lifestyle intervention promoting weight loss and a reduced rate of adverse cardiovascular events, 41 a recent post hoc analysis of risk based on magnitude of weight loss showed that patients who lost more than 10% of their body weight had a 20% reduction in risk of the composite of cardiovascular death, non-fatal acute MI, non-fatal stroke or hospitalisation for angina 42 ; prospective studies are needed to further examine the effects of weight loss on cardiovascular outcomes.
Across Phase 3 studies, canagliflozin 100 and 300 mg have been associated with dose-dependent reductions in body weight.
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Generally, average body weight reductions observed with canagliflozin treatment were between 2% and 5%, 11 and more patients achieved a weight loss of at least 5% or 10% with canagliflozin than with placebo or active comparators. 43, 44 This weight loss was sustained over 104 weeks of treatment in clinical trials. [44] [45] [46] Weight loss associated with canagliflozin and other SGLT2 inhibitors is a result of reductions in both visceral and subcutaneous adipose tissue. [47] [48] [49] [50] Body composition measurements from a Phase 3 study of canagliflozin in patients with T2DM inadequately controlled on metformin showed a mean change in visceral adipose tissue of −7.3% with canagliflozin 100 mg, −8.1% with canagliflozin 300 mg, and 0.1% with glimepiride at 52 weeks; change in subcutaneous adipose tissue was −5.4% with canagliflozin 100 mg, −5.6% with canagliflozin 300 mg and 1.8% with glimepiride. 50 The loss of visceral fat with canagliflozin treatment is noteworthy because visceral fat mass has been shown to increase cardiometabolic risk in patients with T2DM
by promoting atherogenic, thrombotic and inflammatory abnormalities. 47 In addition, visceral adiposity has been associated with concentric left ventricle remodelling, reduced cardiac output and increased systemic vascular resistance. 51 Thus, the weight-related benefits associated with canagliflozin treatment are enhanced by reductions in visceral adiposity that may reduce cardiovascular complications and mortality. and hypertension increases the risk of coronary heart disease and associated mortality dramatically (up to six-fold) compared with either disease alone. 52 Elevated pulse pressure (ie, the difference between systolic and diastolic BP) and mean arterial pressure (ie, the average pressure during a single cardiac cycle [2/3 diastolic BP + 1/3 systolic BP]) also significantly increase CVD risk in patients with T2DM. 53 In a meta-analysis of CVD risk related to pulse pressure and mean arterial pressure, each 10-mmHg incremental increase in pressure was associated with about a 10% increase in risk for CVD. 53 Across Pooled data from four placebo-controlled studies showed that canagliflozin treatment was associated with reductions in pulse pressure, mean arterial pressure and double product (ie, heart rate × systolic BP) compared with placebo. 57 Similar results were observed in a 
| Renal effects
Albuminuria is a well-established marker for CVD and renal disease in patients with T2DM, significantly increasing risk of cardiovascular death. 60, 61 SGLT2 inhibition has been shown to decrease urinary albumin excretion by reducing glomerular filtration rate (GFR) through reduction in glucose and sodium reabsorption in the proximal tubule, which increases sodium delivery to the macula densa in the distal tubule and suppresses activation of tubuloglomerular feedback.
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As an added benefit, reductions in GFR during sympathetic nervous system activation that result from reduced glycaemia and increased hepatic gluconeogenesis may act to stabilise glucose perturbations. 5 Across Phase 3 studies of canagliflozin, early transient reductions in eGFR were observed regardless of baseline renal function. 65 Changes in eGFR generally attenuated to near baseline levels and stabilised over time for all patients, including those with chronic kidney disease (CKD). 56, 66 In studies of patients with CKD, decreases in median albumin-to-creatinine ratio (ACR) were also observed, which were likely a result of volume contraction. 56, 66 A post hoc analysis of results from a Phase 3 study in patients with T2DM inadequately controlled on metformin showed that canagliflozin treatment slowed the progressive decline in eGFR and lowered the ACR compared with glimepiride. 67 The ongoing CANagliflozin cardioVascular Assessment 
| Effects on lipids
Dyslipidaemia plays a critical role in the development of CVD, especially in patients with T2DM, 9 and lipid profile management has become an important component of multifactorial T2DM management. 5 Canagliflozin has been shown to have beneficial effects on highdensity lipoprotein cholesterol (HDL-C) and triglyceride levels, likely as a result of improvements in glycaemic control and reductions in body weight. 69 In pooled placebo-controlled studies, mean placebosubtracted increases in HDL-C were 5.4% and 6.3%, respectively, with canagliflozin 100 and 300 mg at Week 26, and mean placebosubtracted reductions in triglyceride levels were −5.2% and −7.6%, respectively. 69 Canagliflozin has also been shown to increase low-density lipoprotein cholesterol (LDL-C) and total cholesterol relative to placebo. 69 Across four pooled placebo-controlled studies, mean placebosubtracted increases in LDL-C were 4.5% and 8.0%, respectively, with canagliflozin 100 and 300 mg at Week 26. 69 In a pooled analysis of two active-controlled studies, the percentage of patients with LDL-C levels ≥100 mg/dL was not increased from baseline to Week 52 with canagliflozin treatment and was not different at Week 52 with canagliflozin vs sitagliptin. 70 In contrast to results in patients with T2DM who have normal or mild renal impairment, reductions in LDL-C have been seen with canagliflozin in patients with moderate renal impairment over 52 weeks (placebo-subtracted differences of −3.0% and −6.9%
with canagliflozin 100 and 300 mg, respectively). 56 The mechanism for the observed changes in LDL-C with SGLT2 inhibition is not fully understood, but it has been hypothesised that these changes are related to downstream metabolic effects of UGE and haemoconcentration. 71 
| Effects on uric acid
Hyperuricaemia in patients with T2DM is associated with an increased risk of gout, nephropathy, coronary heart disease and mortality. 72, 73 In a meta-analysis of studies that included more than 20 000 patients with T2DM, Xu and colleagues found that for each 100 μmol/L increase in serum uric acid, patients with T2DM experienced a 28% increase in the risk of vascular complications (eg, stroke, coronary heart disease, peripheral vascular disease and nephropathy) and a 9% increase in risk of mortality. 73 Several studies have examined the effects of SGLT2 inhibitors on uric acid levels in patients with T2DM. 62, [74] [75] [76] In Phase 1 studies evaluating the pharmacodynamic effects of canagliflozin in patients with T2DM, fractional urinary excretion of uric acid was increased during the first weeks of treatment with canagliflozin, resulting in a small decrease (~0.1 pH units) in mean urine pH and up to a 20% reduction in serum uric acid levels from baseline to Week 16. 27, 77 These findings were confirmed based on pooled data from four placebo-controlled studies, which showed that patients treated with canagliflozin for 26 weeks had a mean reduction in serum uric acid of ~13% (~0.7 mg/dL) compared with placebo. 74 In the subset of patients with hyperuricaemia at baseline, higher percentages of patients achieved normal uric acid levels (<360 μmol/L [~6 mg/dL]) with canagliflozin 100 mg (23.5%) and canagliflozin 300 mg (32.4%) than with placebo (3.1%). 74 The mechanism by which canagliflozin promotes excretion of uric acid is not well understood, but it has been speculated that SGLT2 inhibition modulates the actions of solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9; also called GLUT9), which exchanges glucose for uric acid. 
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In a meta-analysis of randomised controlled trials of SGLT2 inhibitors in patients with T2DM, Tang and colleagues found that all evaluated drugs (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin)
were associated with modest increases in serum magnesium levels ranging from 0.05 to 0.10 mmol/L. 85 Changes in magnesium levels were similar in patients with normal renal function and with CKD. 85 In a pooled analysis of data from four placebo-controlled studies, canagliflozin was associated with increased serum magnesium levels compared with placebo after 26 weeks of treatment (mean percent changes of 8.1%, 9.3% and −0.6% with canagliflozin 100 and 300 mg and placebo, respectively). 69 Patients with hypomagnesaemia (serum magnesium <0.74 mmol/L) at baseline were more likely to achieve serum magnesium ≥0.74 mmol/L (ie, normal levels) at Week 26 with canagliflozin than placebo. 86 The mechanism for increased serum magnesium with canagliflozin has not been established, but may be related to improvements in insulin sensitivity 37 or changes in the distal convoluted tubule that alter magnesium reabsorption and/or urinary magnesium excretion. 87, 88 It remains to be shown whether normalisation of serum magnesium with SGLT2 inhibitors in patients with T2DM
will affect disease progression or cardiometabolic outcomes.
| Effects on haemoglobin/haematocrit
The relationship between increases in haemoglobin/haematocrit and the risk of CVD is not well defined, with some studies showing variations in risk based on age, gender and type of cardiovascular event. 89 Recent data from the Framingham Heart Study showed that higher haematocrit levels were associated with an increased risk of development of heart failure, even when levels were within normal ranges. 90 In a pooled analysis of data from four placebo-controlled studies, both doses of canagliflozin were associated with increases in haemoglobin compared with placebo. 69 At Week 26, the proportion of patients with increases in haemoglobin of ≥20 g/L from baseline was 6.0% with canagliflozin 100 mg, 5.5% with canagliflozin 300 mg and 1.0% with placebo. Increases in haematocrit from baseline to Week 26 were 5.8% and 6.3% with canagliflozin 100 and 300 mg, respectively, compared with 0.2% in the placebo group. 69 In the EMPA-REG OUTCOME study, the observed modest increases in haematocrit and haemoglobin levels were strongly associated with improvements in heart failure and mortality risk, suggesting that SGLT2 inhibition may affect mechanisms other than (or in addition to) plasma volume contraction to increase haemoglobin levels and thereby oxygen delivery to ischaemic tissues. 
| Effects on ketone bodies
The heart readily consumes ketone bodies and, by some measures, these are a preferred cardiac substrate. 91, 92 Together with changes in other substrate delivery to the heart and potential changes in cardiac insulin sensitivity, increased levels of circulating ketone bodies seen 
| Safety considerations
Overall, canagliflozin has been shown to be generally well tolerated as monotherapy and as part of combination therapy for T2DM. 69 Across four 26-week, placebo-controlled studies, the total incidence of adverse events (AEs) was similar with canagliflozin 100 and 300 mg and placebo. 69 Subsequent analysis of data from seven placebo-and active-controlled studies confirmed the favourable safety profile of canagliflozin for up to 104 weeks. 97 Throughout the clinical development programme, AEs that occurred at a higher rate with canagliflozin vs placebo and other AHA comparators included genital mycotic infections and osmotic diuresis-related AEs, which are related to the mechanism of SGLT2 inhibition. 11 A modest increase in urinary tract infections (UTIs) was seen with canagliflozin 100 and 300 mg vs placebo in the pooled placebo-controlled dataset, but there was no increase in the incidence of serious UTIs with canagliflozin. 69, 98 Due to the reduced efficacy of canagliflozin in patients with renal impairment and the need for more safety data in this population, in the EMPA-REG OUTCOME study. 6 Another thrombotic safety signal was raised that is related to peripheral limb ischaemia based on interim results from CANVAS, which showed higher rates of amputations (mostly toes) with canagliflozin 100 mg (seven of every 1000 patients) and canagliflozin 300 mg (five of every 1000 patients) vs placebo (three of every 1000 patients). 107 However, it should be noted that the patient inclusion and exclusion criteria for CANVAS allowed for enrolment of patients with peripheral arterial disease, which may have affected levels of baseline risk for peripheral limb ischaemia. The EMPA-REG OUTCOME study showed that empagliflozin may provide cardiometabolic benefits that can lead to a reduction in cardiovascular and all-cause mortality in patients with T2DM and established CVD. Of note, the US Food and Drug Administration recently approved a new indication for empagliflozin to reduce the risk of cardiovascular death in adult patients with T2DM and CVD based on results from the EMPA-REG OUTCOME trial. 102 Given the similarities in clinical effects of SGLT2 inhibitors on cardiovascular risk factors, 110 it is possible that these benefits will extend to other drugs in this class. 111 Results from the canagliflozin clinical development programme support that canagliflozin treatment may improve cardiometabolic outcomes in a broad range of patients with diverse clinical characteristics. The potential benefit of this class of agents on persons at risk for congestive heart failure may be particularly important, given the benefits seen in the EMPA-REG OUTCOME trial 112 and the observed effects of SGLT2 inhibitors on BP, volume status and intracardiac filling pressures. 54, 113 Additional data on the cardiovascular and renal effects of canagliflozin in patients with a history or high risk of cardiovascular events will be available upon completion of the large-scale CANVAS Program in 2017. 17, 18, 114 
